ERC Launches Development Program for Novel Cell-Based Therapeutic and Prophylactic SARS-CoV-2 Vaccine

NEXT STORY
Study Shows Guardant360 Test Identifies Predictors of Response to PIK3CA Inhibitors in Women with HR+ Metastatic Breast Cancer
PREV STORY
Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Helmsley Charitable Trust Awards $52 Million to Support the Global Platform for the Prevention of Autoimmune Diabetes

New York, NY, Nov. 06, 2017 (GLOBE NEWSWIRE) -- The Leona M. and Harry ...

author_avatar
NASDAQ Market News

Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis

author_avatar
NASDAQ Market News

Reata Pharmaceuticals, Inc. Appoints David Chapman as Vice President, Marketing

IRVING, Texas, March 24, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (NASDAQ:RETA) (“Reata” or the ...

author_avatar
NASDAQ Market News